Tests etoricoxib added to usual treatment in people with Parkinson disease
Tests etoricoxib alongside L-dopa in adults with Parkinson disease.
Plain-language title generated from the registry record
Registry title: Etoricoxib in Patients With Parkinsonian Disease
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 70 years old?
Source: NCT07370532, who can take part
Where in Egypt
- Mansoura UniversityAl Mansurah, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ihab Elsayed Hassan
- Trial code
- NCT07370532
- Record updated
- 8 April 2026
- Original description
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).Read full original descriptionShow less
Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).
Inclusion: Age ≥ 18 years; Both male and female will be included; Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.
Exclusion: Alcohol and / or drug abusers; Patients who are currently using other anti-inflammatory drugs; Patients with known allergy to the study medications; Breast feeding; Patients with significant liver and kidney function abnormalities; Pregnant women and women with planned pregnancy.